Biomarin Pharmaceutical
BMRN
55.20
-1.02
-1.81%
Biomarin Pharmaceutical
US · BMRN
#1379 by market cap
Listed 1970
55.20
-1.02
-1.81%
Live - 5344 symbols - heartbeat 184s ago
· 2026-10-08 07:00
Pre-market
55.05
-0.27%
After-hours
55.55
+0.63%
- Market cap
- 10.69B
- P/E (TTM)i
- 145.26
- P/Bi
- 1.69
- EPSi
- 1.80
- Div yieldi
- 0.00%
- 52W posi
- 27%
Reader sentiment
Are you bullish or bearish on BMRN?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 21 analysts
Buy
Avg price target
94.89 +71.9%
Price target rangecurrent 55.20
Low62.00
Avg94.89
High124.00
Buy 81%
Hold 19%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-21 | J.P. Morgan | -- | BUY | 86.00 |
| 2026-09-17 | Guggenheim | -- | BUY | 86.00 |
| 2026-09-16 | Morgan Stanley | -- | BUY | 124.00 |
| 2026-09-16 | BMO Capital | -- | BUY | 97.00 |
| 2026-09-14 | Citi | -- | BUY | -- |
| 2026-09-11 | Wells Fargo | -- | BUY | 80.00 |
| 2026-09-01 | Cantor Fitzgerald | -- | BUY | 86.00 |
| 2026-09-01 | Piper Sandler | -- | BUY | 90.00 |
| 2026-09-01 | Morgan Stanley | -- | BUY | 124.00 |
| 2026-08-31 | CCORF | -- | BUY | 114.00 |
| 2026-08-31 | Wells Fargo | -- | BUY | 80.00 |
| 2026-08-31 | William Blair | -- | HOLD | -- |
| 2026-08-31 | Jefferies | -- | BUY | 105.00 |
| 2026-08-31 | Stifel | -- | HOLD | 70.00 |
| 2026-08-31 | Goldman Sachs | -- | HOLD | 70.00 |
| 2026-08-26 | Piper Sandler | -- | BUY | 88.00 |
| 2026-08-20 | TD Cowen | -- | BUY | 120.00 |
| 2026-08-19 | CCORF | -- | BUY | 114.00 |
| 2026-08-19 | Piper Sandler | -- | BUY | 88.00 |
| 2026-08-18 | TD Cowen | -- | BUY | 120.00 |
| 2026-08-18 | William Blair | -- | HOLD | -- |
| 2026-08-18 | BofA Securities | -- | BUY | 86.00 |
| 2026-08-18 | Wedbush | -- | BUY | 94.00 |
| 2026-08-17 | Piper Sandler | -- | BUY | 88.00 |
| 2026-08-17 | Barclays | -- | BUY | 111.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 0 upgrades vs 1 downgrade among tracked analyst rating changes.
- Most recent: Stifel moved from Buy to Hold on 2025-11-06.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2025-11-06 | Stifel | BUY → HOLD | 61.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-06 | After close | ±8.38% | +3.82% (in line) |
| 2026/Q1 | 2026-05-04 | After close | ±8.56% | -4.00% (in line) |
| 2025/Q4 | 2026-02-23 | After close | ±9.97% | -0.48% (in line) |
| 2025/Q3 | 2025-10-27 | After close | ±9.67% | +1.56% (in line) |
| 2025/Q2 | 2025-08-04 | After close | ±7.58% | +2.69% (in line) |
| 2025/Q1 | 2025-05-01 | After close | ±7.85% | -1.08% (in line) |
| 2024/Q4 | 2025-02-19 | After close | ±6.94% | +4.76% (in line) |
| 2024/Q3 | 2024-10-29 | After close | ±7.83% | -4.62% (in line) |
| 2024/Q2 | 2024-08-05 | After close | ±9.80% | +7.95% (in line) |
| 2024/Q1 | 2024-04-24 | After close | ±8.96% | -9.90% (beat) |
| 2023/Q4 | 2024-02-22 | After close | ±9.07% | +1.41% (in line) |
| 2023/Q3 | 2023-11-01 | After close | ±5.89% | -5.17% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 07:00:00 · For reference only, not investment advice and not tailored to your situation.